Comments by "NotMe Us" (@notmeus1968) on "NowThis Impact" channel.

  1. 56
  2. 28
  3. 16
  4. 15
  5. 13
  6. 12
  7. 10
  8. 10
  9. 9
  10. 8
  11. 8
  12. 7
  13. 7
  14. 7
  15. 7
  16. 6
  17. 6
  18. 6
  19. 6
  20. 6
  21. 6
  22. 6
  23. 5
  24. 5
  25. 5
  26. 5
  27. 5
  28. 5
  29. 4
  30. 4
  31. 4
  32. 4
  33. 4
  34. 4
  35. 4
  36. 4
  37. All people, including LGBTQ individuals, were created in God’s image: "So God created humankind in his image, in the image of God he created them; male and female he created them." (Genesis 1:27, NSRV) The use of the two primary genders in this passage is likely a “merism”, a figure of speech by which a single thing (in this case, humanity) is referred to by a phrase that lists several of its parts, but does not list all components. In the other creation passages, day and night are specified, but not twilight; seas and land are mentioned, but not creeks or marshes; vegetation on land but no reference to algae. [10] This passage also indicates that God is not limited to a single gender. There are several characters in the Bible who were non-gender-conforming, meaning that they did not behave according to traditional gender roles, or that they were not physically typical of men or women. [4] Jacob preferred to be with his mother at home, enjoyed cooking and was smooth-skinned, in contrast to his brother, who was hairy and preferred to hunt and be outdoors. (Genesis 25) Joseph, Jacob’s son, was given an “ornate robe” by his father (Genesis 37:3); the Hebrew word used here for the robe (ketonet passim) is used elsewhere to mean “the kind of garment the virgin daughters of the king wore” (2 Samuel 13:18). Deborah (Judges 4-5) was a judge of Israel, acting as a prophet and military leader at a time when women were treated like property and valued by the number of children they could bear. Hegai, the eunuch in charge of the palace women in the story of Esther, helped Esther to become queen. Ebed-Melech also was a eunuch, who saved the life of the prophet Jeremiah (Jeremiah 38). The man carrying a water jar, whom Jesus indicated would take the disciples to the room for his last supper, was doing work that was normally done by women, and yet was given this part to play in Jesus’ ministry (Luke 22:10). The Bible contains feminine images of God, in addition to the masculine metaphors of “Father” and “King”. [7] God’s wisdom in Proverbs is personified as female (Proverbs 1:20, 8:1, 9:1), and Christ is the wisdom of God (1 Corinthians 1:24). Many references to God describe actions associated with women: nurturing life in the womb (Psalm 139:13), giving birth (John 3:5-6), and protecting children (Matthew 23:37). Many early interpreters believed that Adam was androgynous, representing aspects of the archetypical human. [11] The Talmud recognizes six genders that are non-binary or intersex, in addition to male and female
    4
  38. 4
  39. 4
  40. 4
  41. 4
  42. 3
  43. 3
  44. 3
  45. 3
  46. 3
  47. 3
  48. 3
  49. 3
  50. 3
  51. 3
  52. 3
  53. 3
  54. 3
  55. 3
  56. 3
  57. 3
  58. 3
  59. 3
  60. 3
  61. 3
  62. 3
  63. 3
  64. 3
  65. 3
  66. 3
  67. 3
  68. 3
  69. 3
  70. 3
  71. 2
  72. 2
  73. 2
  74. 2
  75. 2
  76. 2
  77. 2
  78. 2
  79. 2
  80. 2
  81. 2
  82. 2
  83. 2
  84. 2
  85. 2
  86. 2
  87. 2
  88. 2
  89. 2
  90. 2
  91. 2
  92. 2
  93. 2
  94. 2
  95. 2
  96. 2
  97. 2
  98. 1
  99. 1
  100. 1
  101. 1
  102. 1
  103. 1
  104. 1
  105. 1
  106. 1
  107. 1
  108. 1
  109. 1
  110. 1
  111. 1
  112. 1
  113. 1
  114. 1
  115. 1
  116. 1
  117. 1
  118. 1
  119. 1
  120. 1
  121. 1
  122. 1
  123. 1
  124. 1
  125. 1
  126. 1
  127. 1
  128. 1
  129. 1
  130. 1
  131. 1
  132. 1
  133. 1
  134. 1
  135. 1
  136. 1
  137. 1
  138. 1
  139. 1
  140. 1
  141. 1
  142. 1
  143. 1
  144. 1
  145. 1
  146. 1
  147.  @whyisntfauciinprison2192  The NIH Letter In the letter, Tabak describes an alleged grant reporting infraction related to an experiment the agency said was conducted in 2018-2019 and related in a progress report EcoHealth submitted in August 2021. The experiment, Tabak said, tested whether spike proteins from bat coronaviruses were capable of binding to human ACE2, the receptor that the viruses use to enter cells, in mice. The experiment is similar to research published in PLOS Pathogens in 2017, which studied two of the same modified viruses. In that paper, researchers used the backbone of WIV1, a bat SARS-like virus reported in 2013, and swapped in the spike proteins of two newly identified bat coronaviruses to see if they, like WIV1, could use the ACE2 receptor to enter human cells grown in a petri dish. They could. This time, the researchers did a similar experiment, but tested the chimeric viruses in mice. Since mice have their own ACE2 receptor, the animals were engineered to express the human form, but were otherwise unchanged. “In this limited experiment, laboratory mice infected with the SHC014 WIV1 bat coronavirus became sicker than those infected with the WIV1 bat coronavirus,” Tabak wrote. “As sometimes occurs in science, this was an unexpected result of the research, as opposed to something that the researchers set out to do.” As is shown in section 3.1 of the grant progress report, which was provided to and released by the Republicans on the House committee, infection with the viruses killed some of the mice, with the one chimeric virus being especially lethal. That virus killed six of the eight mice, replicated better than WIV1 in various mouse tissues and caused more pathology in the lung. Tabak said in his letter that the research plan had been reviewed by the agency before funding, and the agency determined that it did not meet the NIH’s definition of gain-of-function — or what the agency terms research involving enhanced pathogens of pandemic potential — “because these bat coronaviruses had not been shown to infect humans.” It therefore was not subject to review under the Department of Health and Human Services’ framework for enhanced pathogens. But, he added, “out of an abundance of caution and as an additional layer of oversight,” the agency had outlined criteria in the terms and conditions of the grant award for a secondary review, “such as a requirement that the grantee report immediately a one log increase in growth,” meaning a 10-fold increase in viral growth, to “determine whether the research aims should be re-evaluated or new biosafety measures should be enacted.”
    1
  148. 1
  149. 1
  150. 1
  151. 1
  152. 1
  153. 1
  154. 1
  155. 1
  156. 1
  157. 1
  158. 1
  159. 1
  160. 1
  161. 1
  162. 1
  163. 1
  164. 1
  165. 1
  166. 1
  167. 1
  168. 1
  169. 1
  170. 1
  171. 1
  172. 1
  173. 1
  174. 1
  175. 1
  176. 1
  177. 1
  178. 1
  179. 1
  180. 1
  181. 1
  182. 1
  183.  @blackout9587  The NIH Letter In the letter, Tabak describes an alleged grant reporting infraction related to an experiment the agency said was conducted in 2018-2019 and related in a progress report EcoHealth submitted in August 2021. The experiment, Tabak said, tested whether spike proteins from bat coronaviruses were capable of binding to human ACE2, the receptor that the viruses use to enter cells, in mice. The experiment is similar to research published in PLOS Pathogens in 2017, which studied two of the same modified viruses. In that paper, researchers used the backbone of WIV1, a bat SARS-like virus reported in 2013, and swapped in the spike proteins of two newly identified bat coronaviruses to see if they, like WIV1, could use the ACE2 receptor to enter human cells grown in a petri dish. They could. This time, the researchers did a similar experiment, but tested the chimeric viruses in mice. Since mice have their own ACE2 receptor, the animals were engineered to express the human form, but were otherwise unchanged. “In this limited experiment, laboratory mice infected with the SHC014 WIV1 bat coronavirus became sicker than those infected with the WIV1 bat coronavirus,” Tabak wrote. “As sometimes occurs in science, this was an unexpected result of the research, as opposed to something that the researchers set out to do.” As is shown in section 3.1 of the grant progress report, which was provided to and released by the Republicans on the House committee, infection with the viruses killed some of the mice, with the one chimeric virus being especially lethal. That virus killed six of the eight mice, replicated better than WIV1 in various mouse tissues and caused more pathology in the lung. Tabak said in his letter that the research plan had been reviewed by the agency before funding, and the agency determined that it did not meet the NIH’s definition of gain-of-function — or what the agency terms research involving enhanced pathogens of pandemic potential — “because these bat coronaviruses had not been shown to infect humans.” It therefore was not subject to review under the Department of Health and Human Services’ framework for enhanced pathogens. But, he added, “out of an abundance of caution and as an additional layer of oversight,” the agency had outlined criteria in the terms and conditions of the grant award for a secondary review, “such as a requirement that the grantee report immediately a one log increase in growth,” meaning a 10-fold increase in viral growth, to “determine whether the research aims should be re-evaluated or new biosafety measures should be enacted.”
    1
  184. 1
  185. 1
  186. 1
  187. 1
  188. 1
  189. 1
  190. 1
  191. 1
  192. 1
  193. 1
  194. 1
  195. 1
  196. 1
  197. 1
  198. 1
  199. 1
  200.  @GavinCooper05  For transgender individuals, gender-affirming surgery can lead to long-term mental health benefits, according to new research published online today in The American Journal of Psychiatry. The study found that among transgender individuals with gender incongruence, undergoing gender-affirming surgery was significantly associated with a decrease in mental health treatment over time. Researchers Richard Branstrom, Ph.D., and John E. Pachankis, Ph.D., with the Yale School of Public Health, New Haven, Connecticut, used the Swedish Total Population Register to identify more than 2.500 individuals who received a diagnosis of gender incongruence (i.e., transsexualism or gender identity disorder) between 2005 and 2015. Among individuals with gender incongruence, just more than 70% had received hormone treatment and nearly half (48%) had undergone gender-affirming surgical treatment during the 10-year follow-up period. Nearly all (97%) of those who had undergone surgery also received hormone treatment. Less than one-third had received neither treatment. They analyzed mental health treatment in 2015 in relation to the length of time since gender-affirming hormone and surgical treatment, including distinguishing the potentially interrelated effects of the two treatments. The mental health measures included health care visits for mood and anxiety disorder, antidepressant and anti-anxiety prescriptions, and hospitalization after a suicide attempt. Increased time since last gender-affirming surgery was associated with reduced likelihood of use of mental health treatment. The study found the odds of receiving mental health treatment were reduced by 8% for every year since receiving gender-affirming surgery over the 10-year follow-up period. They did not find the same association for hormone treatment. The study also found that compared with the general population, transgender individuals with a gender incongruence were about six times as likely to have had a mood or anxiety disorder health care visit; more than three times as likely to have received prescriptions for antidepressants and anti-anxiety medication; and more than six times as likely to have been hospitalized after a suicide attempt. Despite the reduced mental health treatment use after gender-affirming surgery, treatment use among transgender individuals continued to exceed that of the general population. The authors conclude that “In this first total population study of transgender individuals with a gender incongruence diagnosis, the longitudinal association between gender-affirming surgery and reduced likelihood of mental health treatment lends support to the decision to provide gender-affirming surgeries to transgender individuals who seek them
    1
  201. 1
  202. 1
  203. 1
  204. 1
  205. 1
  206. 1
  207. 1
  208. 1
  209. 1
  210. 1
  211. 1
  212. 1
  213. 1
  214. 1
  215. 1
  216. 1
  217. 1
  218. 1
  219. 1
  220. 1
  221.  @bluerider9204  Anaphylaxis after COVID-19 vaccination is rare and has occurred at a rate of approximately 5 cases per one million vaccine doses administered. Anaphylaxis, a severe type of allergic reaction, can occur after any kind of vaccination. If it happens, healthcare providers can effectively and immediately treat the reaction Thrombosis with thrombocytopenia syndrome (TTS) after J&J/Janssen COVID-19 vaccination is rare and has occurred in approximately 4 cases per one million doses administered. TTS is a rare but serious adverse event that causes blood clots in large blood vessels and low platelets (blood cells that help form clots). Guillain-Barré Syndrome (GBS) in people who have received the J&J/Janssen COVID-19 vaccine is rare. GBS is a rare disorder where the body’s immune system damages nerve cells, causing muscle weakness and sometimes paralysis. GBS has largely been reported in men ages 50 years and older. Based on a recent analysis of data from the Vaccine Safety Datalink, the rate of GBS within the first 21 days following J&J/Janssen COVID-19 vaccination was found to be 21 times higher than after Pfizer-BioNTech or Moderna (mRNA COVID-19 vaccines). After the first 42 days, the rate of GBS was 11 times higher following J&J/Janssen COVID-19 vaccination. The analysis found no increased risk of GBS after Pfizer-BioNTech or Moderna (mRNA COVID-19 vaccines) Myocarditis and pericarditis after COVID-19 vaccination are rare. Myocarditis is inflammation of the heart muscle, and pericarditis is inflammation of the outer lining of the heart. Most patients with myocarditis or pericarditis after COVID-19 vaccination responded well to medicine and rest and felt better quickly. Most cases have been reported after receiving Pfizer-BioNTech or Moderna (mRNA COVID-19 vaccines), particularly in male adolescents and young adults. A review of vaccine safety data in VAERS from December 2020–August 2021 found a small but increased risk of myocarditis after mRNA COVID-19 vaccines. Over 350 million mRNA vaccines were given during the study period and CDC scientists found that rates of myocarditis were highest following the second dose of an mRNA vaccine among males in the following age groups: 12–15 years (70.7 cases per one million doses of Pfizer-BioNTech) 16–17 years (105.9 cases per one million doses of Pfizer-BioNTech) 18–24 years (52.4 cases and 56.3 cases per million doses of Pfizer-BioNTech and Moderna, respectively) As of December 8, 2022, there have been 1,052 preliminary reports in VAERS among people younger than age 18 years under review for potential cases of myocarditis and pericarditis. Of these, 245 remain under review. Through confirmation of symptoms and diagnostics by provider interview or review of medical records, 702 reports have been verified to meet CDC’s working case definition for myocarditis. See below for counts of verified reports of myocarditis by age group. 5-11 years: 23 verified reports of myocarditis after 22,640,548 doses administered 12-15 years: 365 verified reports of myocarditis after 25,465,576 doses administered 16-17 years: 314 verified reports of myocarditis after 13,938,974 doses administered Reports of death after COVID-19 vaccination are rare. FDA requires healthcare providers to report any death after COVID-19 vaccination to VAERS, even if it’s unclear whether the vaccine was the cause. Reports of adverse events to VAERS following vaccination, including deaths, do not necessarily mean that a vaccine caused a health problem. More than 657 million doses of COVID-19 vaccines were administered in the United States from December 14, 2020, through December 7, 2022. During this time, VAERS received 17,868 preliminary reports of death (0.0027%) among people who received a COVID-19 vaccine. CDC and FDA clinicians review reports of death to VAERS including death certificates, autopsy, and medical records. Continued monitoring has identified nine deaths causally associated with J&J/Janssen COVID-19 Thrombosis with thrombocytopenia syndrome (TTS) after J&J/Janssen COVID-19 vaccination is rare and has occurred in approximately 4 cases per one million doses administered. TTS is a rare but serious adverse event that causes blood clots in large blood vessels and low platelets (blood cells that help form clots).. CDC and FDA continue to review reports of death following COVID-19 vaccination and update information as it becomes available
    1
  222. 1
  223. 1
  224. 1
  225. 1
  226. 1
  227. 1
  228. 1
  229. 1
  230. 1
  231. 1
  232. 1
  233. 1
  234. 1
  235. 1
  236. 1
  237. 1
  238. 1
  239. 1
  240. 1
  241. 1
  242. 1
  243. 1
  244. 1
  245. 1
  246. 1
  247. 1
  248. 1
  249. 1
  250. 1
  251. 1
  252. 1
  253. 1
  254. 1
  255. 1
  256. 1
  257. 1
  258. 1
  259. 1
  260. 1
  261. 1
  262. 1
  263. 1
  264. 1
  265. 1
  266. 1
  267. 1
  268. 1
  269. 1
  270. 1
  271. 1
  272. 1
  273. 1
  274. 1
  275. 1
  276. 1
  277. 1
  278. 1
  279. 1